Ascendis Pharma A/SASND
13F holders, Q1 2026 (March 31)8holders
$228.73avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Ascendis Pharma A/S (ASND) in their 13F filings. The largest holders were T. Rowe Price Investment Management, Inc. ($1.4B), T. Rowe Price Associates Inc. ($350.0M) and Driehaus Capital Management LLC ($29.2M).
- Company
- Ascendis Pharma A/S
- CUSIP
- K08588103
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $1.8B |
| Exits | 0 | $0 |
Ownership 8 holders
| T. Rowe Price Investment Management, Inc. | 0.97% | New | 6,162,042 | $1.4B |
| T. Rowe Price Associates Inc. | 0.04% | New | 1,530,345 | $350.0M |
| Driehaus Capital Management LLC | 0.21% | New | 127,562 | $29.2M |
| Q Global Advisors, LLC | 22.27% | New | 100,000 | $22.9M |
| Evolutionary Tree Capital Management, LLC | 3.90% | New | 9,070 | $2.1M |
| Public Employees Retirement System of Ohio | 0.00% | New | 5,784 | $1.3M |
| Legato Capital Management LLC | 0.04% | New | 1,748 | $400K |
| SBI Securities Co., Ltd. | 0.00% | New | 3 | $686 |
"% of holder's portfolio" is ASND's weight in each manager's 13F, not the share of Ascendis Pharma A/S the manager owns.